8-K: LAVA Therapeutics Appoints KPMG as New Auditor, Citing Remediation of Prior Internal Control Weaknesses

LAVA Therapeutics N.V. has announced the appointment of KPMG LLP as its new independent registered public accounting firm for the fiscal year 2025, replacing PricewaterhouseCoopers Accountants N.V., following the remediation of previously identified material weaknesses in internal controls.

Summary

• LAVA Therapeutics N.V. (LVTX) has appointed KPMG LLP (KPMG) as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The decision was approved by the company's board of directors on May 20, 2025, upon the recommendation of the audit committee.
• PricewaterhouseCoopers Accountants N.V. (PwC) was dismissed as the previous auditor.
• PwC's reports for the fiscal years ended December 31, 2023, and 2024, contained no adverse opinions, disclaimers, qualifications, or modifications.
• There were no disagreements with PwC on accounting principles, financial statement disclosure, or auditing scope/procedure.
• PwC had reported material weaknesses in the company's internal control over financial reporting for 2023 and 2024, specifically related to inadequate general controls over information technology (lack of change management, software development life procedures, insufficient user access controls) and the inability to design and maintain appropriate segregation of duties.
• These material weaknesses were remediated as of December 31, 2024, as disclosed in the company's Annual Report on Form 10-K filed on March 28, 2025.
• LAVA Therapeutics did not consult with KPMG on accounting principles or audit opinions prior to their appointment.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful remediation of material weaknesses in internal controls, which enhances financial reporting reliability. The auditor change itself is a neutral corporate governance event, not indicative of underlying financial distress or significant issues, as explicitly stated that there were no disagreements with the prior auditor.

Positives

• The material weaknesses in internal control over financial reporting, identified by the previous auditor, have been remediated as of December 31, 2024, indicating improved financial governance.
• The dismissal of PwC and appointment of KPMG was not due to any disagreements on accounting principles or audit scope, suggesting a smooth transition rather than a contentious one.
• PwC's audit reports for 2023 and 2024 contained no adverse opinions or qualifications, affirming the reliability of past financial statements despite the control weaknesses.

Negatives

• The company previously had material weaknesses in its internal control over financial reporting, specifically concerning IT general controls and segregation of duties, which could have posed risks to financial reporting accuracy.

Risks

• While remediated, the past existence of material weaknesses in internal control over financial reporting (inadequate IT general controls and insufficient segregation of duties) highlights historical control deficiencies that, if not continuously monitored, could recur or impact future financial reporting integrity.

Future Outlook

KPMG LLP has been appointed to audit LAVA Therapeutics N.V.'s U.S. GAAP consolidated financial statements for the fiscal year ending December 31, 2025.

Management Comments

• Fred Powell, Chief Financial Officer, signed the report on behalf of LAVA Therapeutics, N.V.

Industry Context

The change of an independent auditor is a routine corporate governance event for publicly traded companies, often occurring for various reasons including fee negotiations, service scope, or rotation policies. For a biotechnology company like LAVA Therapeutics, maintaining robust internal controls and transparent financial reporting is crucial for investor confidence, especially given the significant R&D investments and regulatory scrutiny common in the sector. The remediation of material weaknesses aligns with broader industry and regulatory expectations for strong financial oversight.

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from improved internal controls and continued independent oversight of financial statements, potentially leading to increased confidence in financial reporting accuracy.
• Investors: Receive assurance that the company is addressing past control deficiencies and maintaining robust financial governance.

Next Steps

• KPMG LLP will audit LAVA Therapeutics N.V.'s U.S. GAAP consolidated financial statements for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

Keywords

LAVA Therapeutics, LVTX, KPMG, PricewaterhouseCoopers, PwC, Auditor Change, Independent Registered Public Accounting Firm, SEC Filing, Form 8-K, Internal Control Over Financial Reporting, Material Weaknesses, Corporate Governance, Biotechnology, Pharmaceuticals